Intrathecal treatment with a vector-based gene therapy was associated with a greater improvement in motor function at 52 ...

Leader of Opposition Suvendu Adhikari donated Rs 10 lakh from his salary towards the treatment of a girl from West Bengal's ...

The FDA has accepted for Priority Review the BLA for apitegromab for the improvement of motor function in patients with spinal muscular atrophy.

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation for its ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

The benefits of weight training are many: it promotes gains in strength and muscle mass, reduces body fat, and contributes to ...

Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it ...

Chugai Pharma’s Evrysdi tablets 5mg receives Japanese approval to treat spinal muscular atrophy: Saturday, March 29, 2025, 11:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd. announ ...